Avillion LLP Company Profile
Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products.
We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market.
Avillion is staffed with a team of expert professionals with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis.
Our offices are in London, United Kingdom, and we are financed by our international investors, Abingworth and Clarus Ventures.
News from Avillion LLP:
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
LONDON, Jan. 9, 2014 /PRNewswire/ — The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULIF® (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and […]
Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer
LONDON, May 28, 2013 /PRNewswire/ — Avillion LLP, which focuses on clinical co-development of therapeutics, today announced the expansion of its leadership team with the appointment of Ramani Varanasi, MSc, MBA, as Chief Business Officer. Ramani is an accomplished business executive, bringing over 18 years of biotechnology and pharmaceutical industry experience to Avillion. She has a […]
